These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8760818)

  • 21. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
    Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
    Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
    Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
    Loftus DJ; Squarcina P; Nielsen MB; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
    Cancer Res; 1998 Jun; 58(11):2433-9. PubMed ID: 9622085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
    Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
    Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
    Abdel-Wahab Z; Kalady MF; Emani S; Onaitis MW; Abdel-Wahab OI; Cisco R; Wheless L; Cheng TY; Tyler DS; Pruitt SK
    Cell Immunol; 2003 Aug; 224(2):86-97. PubMed ID: 14609574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
    Romero P; Gervois N; Schneider J; Escobar P; Valmori D; Pannetier C; Steinle A; Wolfel T; Lienard D; Brichard V; van Pel A; Jotereau F; Cerottini JC
    J Immunol; 1997 Sep; 159(5):2366-74. PubMed ID: 9278327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
    Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
    Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.
    Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG
    Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
    Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC
    Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
    Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
    Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
    Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
    Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
    Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
    Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.